Interpace Diagnostics Reports First Quarter 2019 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Interpace Diagnostics (IDXG) Misses Q1 EPS by 4c, Revenues Miss; Offers FY19 Revenue Outlook
May 13, 2019 4:12 PM EDTInterpace Diagnostics (NASDAQ: IDXG) reported Q1 EPS of ($0.10), $0.04 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $6.01 million versus the consensus estimate of $6.33 million.
FIRST QUARTER 2019 FINANCIAL PERFORMANCE
Net Revenue was $6.01 million, an increase of 25% over the first quarter of 2018;Gross Profit was 56%, an improvement compared to 46% in the first quarter of 2018;Sales & marketing Expenses, were $2.4 million or 40% of Net Revenues an improvement as... More